Meddenovo Drug Design
Antoine MARION is a co-founder and CTO at Meddenovo Drug Design since July 2021. Prior to this role, Antoine served as an Assistant Professor at Middle East Technical University from February 2018 to September 2023, and as a Postdoctoral Research Scientist at Technische Universität München from January 2015 to August 2017. Antoine's research includes the development of corrections to semiempirical (NDDO) quantum mechanical methods and original protocols for studying protein/ligand binding. Antoine also has experience as a Research Assistant at CNRS, focusing on force field parameter development, and as a PhD Student in Theoretical Chemistry at Université de Lorraine, where a Molecular Dynamics Method using a Quantum SemiEmpirical Hamiltonian was developed. Educational qualifications include a PhD in Theoretical Chemistry from Université de Lorraine, a Master’s degree from Université de Franche-Comté, and a Bachelor’s degree in Chemistry from the same university. Additional roles include being Vice-President of the Youth Club of the French Chemical Society and various positions in retail and tutoring.
This person is not in any teams
This person is not in any offices
Meddenovo Drug Design
Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.